hs-CRP marker predicts long-term risk and benefits of therapy
This article was originally published in Clinica
Measuring levels of the inflammatory marker hs-CRP before patients with atherosclerosis undergo percutaneous interventions (PCI) could help predict their outcomes and identify those who would benefit the most from long-term clopidogrel and aspirin therapy.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.